Bio Saga Feed

India, UK based Anuva ties up with US genomics major

noreply@blogger.com (Bio Saga) — Wed, 31 Aug 2022 05:18:00 +0000

Anuva, with its centre of operations based in India and supported by a Cambridge ..

Webinar Announcement | Chromatography Data System for regulated Laboratories | Part 2 – Get the most out of CDS

Build a more Secure, Connected and Regulated Bioequivalence Lab

noreply@blogger.com (Bio Saga) — Thu, 23 Jul 2020 15:25:00 +0000

Electronic records obtained from LCMSMS analysis Data Systems are required to be securely archived (Data Management System), maintained throughout the lifecycle of the data, and backed up (Scientific Data Management System). Data for BE studies are often transferred electronically between organizations involved in the studies, verification that the software used by each organization is compatible with the others and that there is no impact on the data so-transferred, should be conducted before commencing key study-related tasks. Join us to learn deeper into this subject.

Webinar Announcement: Build a more secure, connected and regulated Bioequivalence Lab

LabCast Session: Effective ways of managing scientific data in analytical labs

noreply@blogger.com (Bio Saga) — Fri, 12 Jun 2020 05:02:00 +0000

Effective data management is a crucial piece of deploying the IT systems that run lab applications and provide analytical information to help drive scientific and operational decision-making and strategic planning by executives, managers, and end-users. Register for this webinar

https://www.linkedin.com/posts/kameshwaran_labcast-session-effective-ways-of-managing-activity-6676769940088856576-e9Vh

An Ecosystem for a Digital Lab - Aspects and Possibilities

noreply@blogger.com (Bio Saga) — Mon, 27 Apr 2020 09:45:00 +0000

What is the future lab going to be, what are the visions for a smart lab a digital lab?

https://lnkd.in/g2jfB6C

Data Integrity for Non-Chromatography analytical instruments and Risk mitigation for standalone workstation data

noreply@blogger.com (Bio Saga) — Fri, 10 Apr 2020 14:00:00 +0000

Join us for a live LabCast on 15 April 3 pm onwards to discuss on Data Integrity for Non-Chromatography analytical instruments and Risk mitigation for standalone workstation data.

https://www.linkedin.com/posts/kameshwaran_managing-compliance-data-integrity-for-activity-6654326452684713984-GjKi

Autocalculations and learn about eliminating excel based components!

noreply@blogger.com (Bio Saga) — Mon, 06 Apr 2020 12:16:00 +0000

Autocalculations and learn about eliminating excel based components!

Would you like to know more?

Join this Agilent LabCast on Autocalculations and learn about eliminating excel based components, while enhancing productivity and reducing human-errors.

https://www.linkedin.com/posts/kameshwaran_welcome-you-are-invited-to-join-a-meeting-activity-6652880875912511488-VZkA

LabCast Session: Get the Most Out of Your Chromatography Data System

noreply@blogger.com (Bio Saga) — Fri, 27 Mar 2020 07:24:00 +0000

Live Labcast: Enhance productivity with ease of use. Get the Most Out of Your Chromatography Data System with Agilent OpenLab CDSJoin us for live labcast on 30th March, 2020 from 3-4pm

https://www.linkedin.com/posts/kameshwaran_labcast-session-get-the-most-out-of-your-activity-6648872465445552128-59f-

Data Integrity is your issue? How can I get tips on handling compliance queries during audits?

noreply@blogger.com (Bio Saga) — Fri, 20 Mar 2020 08:08:00 +0000

Data Integrity is your issue? How can I get tips on handling compliance queries during audits? Why data review process is so important ? Need answers to these questions? Join us for a live Labcast on Enhanced compliance, data integrity and tips on how to face audits on 23rd March from 3PM to 4PM IST https://lnkd.in/ffFZPTj

https://www.linkedin.com/posts/kameshwaran_openlab-cds-enhanced-compliance-data-integrity-activity-6646664205363712000-a_LL

Thermo Fisher Scientific to Acquire QIAGEN N.V.

noreply@blogger.com (Bio Saga) — Fri, 06 Mar 2020 09:11:00 +0000

• Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing
• Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies
• Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close

WALTHAM, Mass. and VENLO, The Netherlands – March 3, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.

The transaction values QIAGEN at approximately $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt.

“We are excited to bring together our complementary offerings to advance our customers’ important work, from discovery to diagnostics,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies.”

QIAGEN is a leading provider of life science and molecular diagnostic solutions and employs approximately 5,100 people at 35 locations in more than 25 countries. The company generated 2019 revenue of $1.53 billion. Its sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples. The company’s assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, QIAGEN’s instruments can be used to automate these workflows, while its bioinformatics systems provide customers with relevant, actionable insights.

“Our vision at QIAGEN has always been to make improvements in life possible with our differentiated Sample to Insight molecular testing solutions,” said Thierry Bernard, interim chief executive officer of QIAGEN N.V. and senior vice president, head of the molecular diagnostics business area. “This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact. The combination is designed to deliver significant cash value to our shareholders, while enabling us to accelerate the expansion of our solutions to provide customers worldwide with breakthroughs that advance our knowledge about the science of life and improve health outcomes.”

Casper concluded, “We look forward to welcoming QIAGEN’s employees to Thermo Fisher and are excited about the new opportunities we’ll have to advance precision medicine through new molecular diagnostics and improved life sciences workflows.”

would you like to know more?

Research Training - An exclusive six months course

noreply@blogger.com (Bio Saga) — Tue, 05 Nov 2019 04:15:00 +0000

Modules

▪	Bioinformatics

▪	Chemoinformatics

▪	Computer Aided Drug Discovery

▪	Molecular Modeling and Dynamics

▪	NGS Data Analysis

▪	Python and Bio-Python

▪	Perl and Bio-Perl

Features

▪	Two Months Hands-on-training

▪	Four Months Extensive Project

▪	Research Paper Publication

▪	Review Paper Publication

▪	6-Months Experience letter

▪	100% Job Assistance

▪	4 Interview calls

▪	HR sessions

▪

CV Making

Apply today

Applications invited for PhD in Computational Biology

noreply@blogger.com (Bio Saga) — Tue, 05 Nov 2019 04:12:00 +0000

IIIT-Delhi invites applications for admission in Ph.D. - Computational Biology (CB) program. We request you to share the information with potential candidates.

Open Positions in below Research Areas:

Decoding Cancer Hacking Mechanisms

Computational Biochemistry, Mathematical, and systems biology modeling of metabolic networks

of cancer systems

Computational protein engineering

Computational Biology, Network Biology, Systems Biology of Cancer and other Complex Diseases,

Computational Gastronomy, Artificial Intelligence, Biomedical Data Informatics, Complex Networks,

Natural Language Processing, Machine Learning, Data Analytics, and Mining

For more information about our eligibility criteria, admission, selection process, please refer to our website: https://www.iiitd.ac.in/admission/phd/nov2019

Center for Computational Biology @IIITD focuses on educational research at the interface of biological and computational sciences. For more information about our program, faculty, research, collaboration, please visit our website: https://cb.iiitd.ac.in/

CCB Facebook page - www.facebook.com/CCB.IIITDelhi/

CCB Twitter page: https://twitter.com/CompBio_IIITD

Data Management Challenges In Next Generation Sequencing

noreply@blogger.com (Bio Saga) — Wed, 23 Oct 2019 07:39:00 +0000

Recently I had shared a piece of news on the same topic:- https://www.linkedin.com/feed/update/urn:li:activity:6590633791084163072/

Data Management Challenges In Next Generation Sequencing

Since the beginning of the Human Genome Project, data management has been perceived as a key challenge for current molecular biology research. Before the finish of the nineties, advances had been set up that adequately bolstered most continuous activities, ordinarily based upon relational database management frameworks. Ongoing years have seen a sensational increment in the amount of information created by running projects that extends in this area. While it took over ten years, roughly three billion USD, and in excess of 200 gatherings worldwide to collect the main human genome, the present sequencing machines create a similar amount of crude information in seven days, at an expense of around 2000 USD, and on a solitary gadget. A few national and international projects presently manage a huge number of genomes, and patterns like personalized drug call for endeavors to sequence the whole population. To know more Click on the following Button

Know More

Breakthrough gene-editing tool can find and replace DNA better than CRISPR

noreply@blogger.com (Bio Saga) — Tue, 22 Oct 2019 12:22:00 +0000

"Prime editing" is more precise and more efficient than CRISPR and could herald a new era of genetic manipulation.

The ability to edit the genes of human beings by changing the code of life -- DNA -- has dramatically improved over the last decade. Current tools, like CRISPR-Cas9and base editors, are extremely powerful but have traditionally suffered from a lack of precision, high error rate and limited scope, hampering their ability to treat human genetic disease. A breakthrough gene-editing tool, developed by a team of researchers at Harvard University and unveiled Monday, has the ability to make extremely precise DNA edits, ushering in a new era of genetic manipulation.

"In many respects this first report is the beginning rather than the end of a longstanding aspiration ... to be able to make any DNA change in any position of a living cell or organism including, potentially, human patients with genetic diseases," says David Liu, a chemist at Harvard's Broad Institute and co-author of the new study.

https://www.cnet.com/google-amp/news/breakthrough-gene-editing-tool-can-find-and-replace-dna-better-than-crispr/

How CRISPR lets us edit our DNA

noreply@blogger.com (Bio Saga) — Fri, 04 Oct 2019 17:04:00 +0000

https://youtu.be/TdBAHexVYzc

CRISPR Gene Editing Is Being Tested in Human Patients, and the Results Could Revolutionize Health Care

noreply@blogger.com (Bio Saga) — Wed, 07 Aug 2019 16:27:00 +0000

https://time.com/5642755/crispr-gene-editing-humans/?amp=true

It’s only been seven years since scientists first learned how to precisely and reliably splice the human genome using a tool calledCRISPR, making it possible to think about snipping out disease-causing mutations and actually cure, once and for all, genetic diseases ranging from sickle cell anemia to certain types of cancer and even blindness.

Doctors are plunging ahead in search of ways to use the relatively new technology to start treating patients. In China last November, scientist Jiankui He stunned—and dismayed—the genetic community when he announced he had already used CRISPR, which many believe still hasn’t been proven either safe or effective in human patients, topermanently alter the genomes of twin girlsto be immune to HIV infection. He’s experiment was criticized because he edited the twins’ cells when they were embryos, therefore ensuring that every one of their cells is now changed, including their reproductive ones, which means their edited genomes can be passed on to their children, despite the fact that experts can’t be sure what the long term effects of such lasting modifications might be.CRISPR Gene Editing Is Being Tested in Human Patients, and the Results Could Revolutionize Health Care

First U.S. Patients Treated With CRISPR As Human Gene-Editing Trials Get Underway

noreply@blogger.com (Bio Saga) — Mon, 06 May 2019 09:58:00 +0000

https://singularityhub.com/2019/05/02/crispr-used-in-human-trials-for-the-first-time-in-the-us/amp/

CRISPR just hit another landmark.

Last week, the University of Pennsylvania (UPenn) confirmed that they have treated two cancer patients using the gene editing darling married with another biomedical wizard, CAR-T. For now, it’s too early to tell if the treatment proved beneficial in either patient, but the team hopes to release a first batch of results in a conference or journal “at an appropriate time.”

It marks CRISPR’s first debut onto the US clinical scene, and it’s a long time coming. As early as mid-2016 the team had already received approval from the FDA to move ahead with their concept. Yet they didn’t register the trial until early 2018, taking careful precautions to not royally mess up CRISPR’s introduction into the biomedical mainstream.

This is in stark contrast to China, which, due to laxer clinical registration rules, kicked off its first CRISPR-for-cancer clinical trial in 2017 and is now tentatively ahead in the global race for CRISPR dominance.

So why the precautions? Because the history behind UPenn and gene editing is complicated, to say the least.

At the turn of the century, while riding high on the promise of genetic tinkering as a medical “silver bullet,” UPenn bid on a daring gene therapy treatment for an 18-year-old patient called Jesse Gelsinger. He died.

Gelsinger’s death is now widely considered the event that set gene therapy back by decades. Subsequent investigations into the trial found multiple problems, including underreported data on the treatment’s side effects in animals and numerous conflicts of interest.

Obviously, a lot is riding on the new trial. And Gelsinger’s tragedy looms as a cautionary tale as the team readily moves forward. Yet the meeting of CRISPR with CAR-T is akin to a final Winterfell reunion, teamed up and poised to battle against one of humanity’s darkest, cruelest threats (Apologies to non Game of Thrones fans!).

“2019 is the year when the training wheels come off and the world gets to see what CRISPR can really do for the world in the most positive sense,” said gene-editing expert Dr. Fyodor Urnov at the Altius Institute for Biomedical Sciences in Seattle, who is not involved in the trial.

Here’s what you need to know.

How Does it Work?

Although the UPenn study marks CRISPR’s first foray into humans in the US, the technology actually plays second fiddle here.

The main star is CAR-T, the revolutionary cancer therapy that “levels up” the body’s immune cells with clever genetic hacks. The first therapy of this type, Kymriah by Novartis, was approved by the FDA for some childhood treatment-resistant blood cancers in 2017.

Here, doctors extract a patient’s own T cells, a type of white blood cell that normally acts as the body’s watcher against cancer and infection. Cancer cells eventually learn to evade T cells or disarm the troops—while turning their own surrounding normal cells into cancerous ones, thus expanding their tumor legion.

CAR-T uses gene therapy to recharge those beaten-down T cells. The UPenn study, for example, relies on a neutered HIV-like virus to deliver an artificial “tracker” protein into those cells. These designer trackers expertly hunt down a protein dubbed NY-ESO-1, which dot certain cancer cells’ surface like a homing beacon.

CRISPR amplifies the CAR-T effect: the team is using the gene editing tool to erase three different “brakes” in T cells. Killing off the first two, TCR α and TCR β, keeps the edited cells in check to prevent friendly autoimmune fire, and allows the added “tracker proteins” to thrive in large numbers. Wiping out the third, PD-1, prevents a phenomenon called T cell exhaustion. It’s aptly named: here, tumor cells secrete molecules that literally shut down T cell activity, zapping away their killing power.

These edited T cells are then expanded in the lab into hundreds of millions before being infused back into the patient.

Combining CAR-T and CRISPR, in theory, could have “improved anti-tumor activity and enhanced persistence,” wrote Dr. Francoise Baylis at Dalhousie University in a 2017 commentary, who is not involved in the trial.

“Cell therapies [for cancer] are so promising, but the majority of people who get these therapies have a disease that relapses,” said study leader Dr. Edward Stadtmauer to Nature at the time, adding that CRISPR could eliminate CAR-T’s vulnerabilities to cancer and the body’s own immune system.

The Trial

So far, the UPenn team has treated two cancer patients with the therapy. Both had relapsed following standard treatment, and the experimental trial offers new hope. One patient has multiple myeloma, which forms from plasma cells, a type of white blood cell in the bone marrow. The other has sarcoma, which is a relatively rare type of cancer affecting connective tissues.

Both patients had their natural white blood cells depleted using chemotherapy drugs before the infusion, thus making way for the super-charged T cells to take their place.

The main point here, stresses the team in the trial’s registration documents, is less about the treatment’s effectiveness and more about safety. One main measure is to track the patient’s response after a single infusion of the super-cells and monitor for signs of toxicity.

It’s no small deed: Gelsinger died from gene therapy side effects in which his immune system went haywire and shut down his organs and brain in just four days. Because CAR-T and CRISPR are both toying with the immune system, the team is extra careful to monitor the patients for any signs of an impending immunological hurricane.

The second measure is more practical: the team hopes to obtain data on the feasibility of manufacturing quadruple-edited T cells, which is an engineering nightmare. For example, the virus used in CAR-T could run wild, inserting multiple copies of a gene when it isn’t supposed to. Or it could not do its gene-delivery job. CAR-T cells could simply not survive another round of CRISPR editing.

We have to carefully check the gene-disrupted T cells for purity, viability, efficiency and guard against tumor contamination, the team wrote. This first step is expected to take up to five years.

Meanwhile, the team will also be monitoring the patients for a rough first gauge of effectiveness: if the therapy can beat back the cancers, and if so, how long the patients are in remission and their overall survival rates. In all, the team hopes to recruit 18 patients for this initial study—a very small sample size. However, considering the dangers, the trial represents a laudable, deliberate first step to unleashing CRISPR’s powers in humans.

An Uncertain Future

The therapy could very well not work.

Because CRISPR is just an add-on therapy to CAR-T, the patients may not respond to CAR-T, regardless of CRISPR’s contributions. The two technologies could also clash against one another in unexpected ways rather than work in synchrony.

Then there are problems with off-target effects, especially from CRISPR. Editing more than one gene increases the chance of deleting an innocent, non-targeted essential gene, or turning CAR-T cells themselves precancerous. Recent results suggest that cells that survive CRISPR editing also tend to be those likely to turn against the body.

Some scientists also argue that there hasn’t been a sufficient amount of animal trials—with large enough samples—to justify the trial going forward in humans. But the team argues that their previous results have gone through careful, extensive review in both scientific merit and ethics.

The UPenn study isn’t the only CRISPR trial on the horizon—it just made it first in the US. Earlier this year in Europe a patient was treated with CRISPR for beta thalassemia, an inherited blood disease. Additional trials for sickle cell disease and inherited blindness are also rushing towards human trials.

As with any groundbreaking experimental therapy, there are no guarantees.

“Every human on the planet should hope that this technology works. But it might work. It might not,” said bioethicist Dr. Laurie Zoloth at the University of Chicago. “Any first use in humans we have to be extraordinarily careful.”

But to Dr. Mildred Cho, a bioethicist at Stanford University, animal safety experiments for something completely revolutionary can only go so far. She said, “Often we have to take the leap of faith.”

Japan okays research using human cells in animals

noreply@blogger.com (Bio Saga) — Tue, 19 Mar 2019 07:41:00 +0000

Japan has given the green light to a controversial research process involving implanting animals with human stem cells that could eventually help grow human organs for transplant inside animal hosts.

Workshop On Bioinformatics and Protein Structure Prediction

noreply@blogger.com (Bio Saga) — Fri, 15 Mar 2019 04:43:00 +0000

Know About Our Workshop On Bioinformatics and Protein Structure Prediction

10th to 12th May 2019 | Pune, India | 09:30 AM - 05:00 PM

Our 3 day comprehensive workshop on Bioinformatics and Protein Structure Prediction aims at providing systematic Hands-on-Training on Protein visualization, mutation & other manipulations.Understand concept of in-silico protein modelling using servers & software’s.Understanding concept of protein motif and domains.Understanding concept of protein structure prediction by Modeller

COMPREHENSIVE & SEQUENTIAL SESSIONS ON:

▪	Introduction to Biological databases

▪	Multiple Sequence Alignment – CLUSTALW

▪	Introduction to Proteins & Protein Databases-UNIPROT

▪	Study of proteins and their structures

▪	Protein Secondary Structure Prediction tools

▪	Protein Tertiary Structure Prediction using Servers & Modeller

▪	Protein Structure Validation with Ramachandran Plot

▪	Protein Structure Energy Minimization

Group Discount Available

For Further Details, Contact

Mail us At- info@rasalsi.com

For Quick Response WhatsApp +91-7798668315,91-7038770985,

Registered participants will be required to carry their own laptop for a hands-own practice of data analysis.

Japan OKs research using human cells in animals

noreply@blogger.com (Bio Saga) — Tue, 05 Mar 2019 05:50:00 +0000

Japan has given the green light to a controversial research process involving implanting animals with human stem cells that could eventually help grow human organs for transplant inside animal hosts.

The decision by the education and science ministry Friday to revise its guidelines means Japanese researchers can now apply for permits to carry out studies employing the technique, a ministry official told AFP.

The process involves implanting embryonic animals, likely first pigs, with human "induced pluripotent stem" (iPS) cells, which can transform into the building blocks of any part of the body.

The idea is for the iPS cells to grow into transplantable human organs inside the animal embryos.

Japan had previously required researchers to terminate animal embryos implanted with human cells after 14 days "due to ethical concerns over the vague line between human beings and animals," the official said.

The old regulations also prevented researchers from placing the embryos into animal wombs to allow them to develop.

But the ministry has dropped both restrictions "as we have concluded that there is technically zero risk of producing a new organism mixing human and animal elements under the research," the official added.

Researchers will now, for instance, be allowed to create animal embryos with a human pancreas and transplant it into the womb of a pig, which could in theory result in the birth of a baby pig with a human pancreas.

In practice, where similar research has been carried elsewhere, the embryos have been terminated before delivery, avoiding the thorny moral issues raised by creating creatures that contain both human and animal cells.

Research involving the hybrids sometimes called "chimeras" -- after the monster in Greek mythology with a lion's head, goat's body and dragon's tail -- has been controversial elsewhere too.

Ethical questions have been raised about the status of animals containing human cells, and whether human iPS cells implanted into animals could develop into brain matter or reproductive organs.

But a shortage of transplantable human organs means researchers around the world are racing to create mixed human-animal embryos.

Do your proteins have their own social network?

noreply@blogger.com (Bio Saga) — Wed, 13 Feb 2019 13:00:00 +0000

Heres-why-the-rise-of-superbugs-is-so-dangerous

noreply@blogger.com (Bio Saga) — Wed, 30 Jan 2019 06:12:00 +0000

https://www.washingtonpost.com/video/national/health-science/heres-why-the-rise-of-superbugs-is-so-dangerous/2019/01/23/234dd347-6a74-4a0e-a203-5d9551035495_video.html

https://www.washingtonpost.com/video/national/health-science/heres-why-the-rise-of-superbugs-is-so-dangerous/2019/01/23/234dd347-6a74-4a0e-a203-5d9551035495_video.html?noredirect=on&utm_term=.4e7c09b944fa

"Molecular Tweeting" Could Hold the Key to Busting Superbugs

noreply@blogger.com (Bio Saga) — Wed, 30 Jan 2019 05:30:00 +0000

"Molecular Tweeting" Could Hold the Key to Busting Superbugs

A broader understanding of bacterial social networks might help scientists combat antibiotic resistance

Indeed interesting, although bit old article, sounded very interesting. Just stumbled on it this morning!

3 Days National Level Workshop on "NGS Data Analysis:Variant Calling,RNASEQ,CHIPSEQ"'

noreply@blogger.com (Bio Saga) — Wed, 30 Jan 2019 05:17:00 +0000

3 Days National Level Workshop on "NGS Data Analysis:Variant Calling,RNASEQ,CHIPSEQ"'

8th to 10th March 2019

09:30 AM - 05:00 PM

Topics Covered

▪	Introduction to Bioinformatics

▪	Data curation using Biological databases

▪	Understanding the concept of Gene Expression & Genome Editing

▪	Gene Finding Tools

▪	Introduction to Next Generation Sequencing

▪	Searching for SRA Data for genomic samples

▪	Introduction to Sequence alignment, BLAST

▪	Variant Calling to detect mutations

▪	RNA sample studies for gene expression

▪	Introduction to ChIP-Seq technology

Our 3 days comprehensive Workshop on Next Generation Sequencing Data Analysis,Variant Calling, RNAseq, ChIPseq : A Practical Introduction aims at providing systematic Hands-on-Training on using Data Analysis application/tools for the NGS data. This workshop had been conceptualized by eminent scientist having substantial experience in the field of Data Analysis.

Know More

Registration Details

Early Bird Date - upto 31/1/2019

Graduate and Undergraduate Students - Rs. 3000/-
Professors/Researchers/phd research scholar - Rs. 3500/-
working Professional-4000/- *NRI/Foreign Nationals - Rs .5000/-

Standard Registration - 01/02/2019 - 02/03/2019

Graduate and Undergraduate Students - Rs. 3500/-
Professors/Researchers/phd research scholar - Rs. 4000/-
working Professional-4500/- *NRI/Foreign Nationals - Rs .5500/-

Onspot Registration - 03/03/2019 -07/03/2019

Graduate and Undergraduate Students - Rs. 4000/-
Professors/Researchers/phd research scholar - Rs. 4500/-
working Professional-5000/- *NRI/Foreign Nationals - Rs .6000/-

Contact Details-072760 10408, 7798668315

National level Workshop on 'Bioinformatics and Precision Genomics'

noreply@blogger.com (Bio Saga) — Fri, 28 Dec 2018 07:07:00 +0000

Limited Seats

National level Workshop on 'Bioinformatics and Precision Genomics'

18th - 19th January 2019

09:30 AM - 05:00 PM

Topics Covered

▪	Introduction to Bioinformatics

▪

CRISPR

▪	Data Mining from Biological Databases

▪	Sequence Alignment

▪	Primer Designing

▪	Concept of Phylodynamics

▪	Gene Expression and Genome editing

▪

EBI Tools

▪	SRA Data for genomic samples

Our 2 days comprehensive workshop on “BIOINFORMATICS & PRECISION GENOMICS” aims at providing systematic Hands-on-Training on using advanced Bioinformatics and Genomic application/tools. This workshop had been conceptualized by eminent scientist having substantial experience in the field of structural biology..

Know More

Registration Details

Early Bird Date - upto 31/12/2018

Graduate and Undergraduate Students - Rs. 2000/-
Professors/Researchers/phd research scholar - Rs. 3000/-
NRI/Foreign Nationals - Rs .4000/-

Regular Registration - 01/01/2019 - 18/01/2019

Graduate and Undergraduate Students - Rs. 2500/-
Professors/Researchers/phd research scholar - Rs. 3500/-
NRI/Foreign Nationals - Rs .4500/-

Contact Details-072760 10408, 7798668315, 7038770985, 7875793891